Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

The expression of Death Inducer-Obliterator (DIDO) variants in Myeloproliferative Neoplasms

Full text
Show less -
Berzoti-Coelho, Maria Gabriela [1] ; Ferreira, Aline Fernanda [2, 1] ; Nunes, Natalia de Souza [1] ; Pinto, Mariana Tomazini [2, 1] ; Rocha Junior, Maur-Cio Cristiano [2, 1] ; Simoes, Belinda Pinto [2, 3] ; Martinez-A, Carlos [4] ; Souto, Elizabeth Xisto [5] ; Panepucci, Rodrigo Alexandre [2, 3] ; Covas, Dimas Tadeu [2, 3] ; Kashima, Simone [2, 1] ; Castro, Fabiola Attie [2, 1]
Total Authors: 12
[1] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Dept Clin Anal Toxicol & Food Sci, BR-09500900 Sao Paulo - Brazil
[2] Ctr Cell Based Therapy, Ribeirao Preto - Brazil
[3] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Internal Med, BR-09500900 Sao Paulo - Brazil
[4] Univ Autonoma Madrid, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Campus Cantoblanco, Madrid - Spain
[5] Hosp Transplantes Euryclides Jesus Zerbini, Sao Paulo - Brazil
Total Affiliations: 5
Document type: Journal article
Source: BLOOD CELLS MOLECULES AND DISEASES; v. 59, p. 25-30, JUL 2016.
Web of Science Citations: 4

Chronic Myeloid Leukemia (CML), Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF) are Myeloproliferative Neoplasms (MPN) characterized by clonal myeloproliferation without cell maturation impairment. CML pathogenesis is associated with the Ph chromosome leading to BCR-ABL tyrosine-kinase constitutive expression. The Ph negative MPN (PV, ET and PMF) are characterized by the mutation JAK2(V617F) of the JAK2 protein in the auto-inhibitory JH2 domain, which is found in most PV patients and in approximately half of ET and PMF patients. Considerable effort is beingmade to understand the role of JAK2(V617F) at the MPN initiation and to clarify the pathogenesis and apoptosis resistance in CML, PV, ET and PMF patients. In the present investigation, we evaluated the Death Inducer-Obliterator (DIDO) (variants DIDO 1, 2 and 3) levels in CML, PV, ET and PMF patients. Our data reported the DIDO1, 2 and 3 differential expressions in Myeloproliferative Neoplasms. (C) 2016 Elsevier Inc. All rights reserved. (AU)

FAPESP's process: 11/20135-2 - Molecular and epigenetic analysis in JAK2 V617F-positive and -negative chronic myeloproliferative neoplasms
Grantee:Fabíola Attié de Castro
Support Opportunities: Regular Research Grants